Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Mayne Pharma Group Limited (MAYNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.082x
Based on the latest financial reports, Mayne Pharma Group Limited (MAYNF) has a cash flow conversion efficiency ratio of 0.082x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.50 Million) by net assets ($370.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mayne Pharma Group Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mayne Pharma Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mayne Pharma Group Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bonava AB (publ)
ST:BONAV-B
|
0.063x |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
-0.267x |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
0.042x |
|
SANIONA AB (PUBL)
F:30S
|
N/A |
|
Seven West Media Limited
PINK:WANHY
|
N/A |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
0.041x |
|
Bonava AB B
LSE:0RHA
|
-0.108x |
|
Binh Dinh Pharmaceutical and Medical Equipment JSC
VN:DBD
|
0.130x |
Annual Cash Flow Conversion Efficiency for Mayne Pharma Group Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Mayne Pharma Group Limited from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $370.28 Million | $17.47 Million | 0.047x | +240.05% |
| 2024-06-30 | $454.19 Million | $-15.30 Million | -0.034x | +49.97% |
| 2023-06-30 | $634.36 Million | $-42.71 Million | -0.067x | -420.56% |
| 2022-06-30 | $557.12 Million | $-7.21 Million | -0.013x | -116.95% |
| 2021-06-30 | $771.58 Million | $58.86 Million | 0.076x | -20.31% |
| 2020-06-30 | $1.04 Billion | $99.78 Million | 0.096x | -8.94% |
| 2019-06-30 | $1.01 Billion | $106.61 Million | 0.105x | +6.87% |
| 2018-06-30 | $1.24 Billion | $121.50 Million | 0.098x | +947.27% |
| 2017-06-30 | $1.31 Billion | $-15.24 Million | -0.012x | -108.16% |
| 2016-06-30 | $376.22 Million | $53.50 Million | 0.142x | +104.38% |
| 2015-06-30 | $322.20 Million | $22.42 Million | 0.070x | -57.60% |
| 2014-06-30 | $159.27 Million | $26.14 Million | 0.164x | +189.81% |
| 2013-06-30 | $120.89 Million | $6.84 Million | 0.057x | -87.06% |
| 2012-06-30 | $30.60 Million | $13.39 Million | 0.437x | +158.83% |
| 2011-06-30 | $24.17 Million | $4.09 Million | 0.169x | -57.89% |
| 2010-06-30 | $25.55 Million | $10.26 Million | 0.401x | +186.15% |
| 2009-06-30 | $7.70 Million | $-3.59 Million | -0.466x | -76.14% |
| 2008-06-30 | $11.44 Million | $-3.03 Million | -0.265x | -209.97% |
| 2007-06-30 | $14.51 Million | $-1.24 Million | -0.085x | -- |